The NOAC market, which is worth 230 billion won, fell for the first time last year. This is because the generic market for some items was opened and drug prices were cut. Generics, which competed with the original "Xarelto," secured a market worth 9 billion won last year. According to Ubist, a pharmaceutical market research firm on the 8th, the size of the outpatient prescription market in the NOAC market last year was 227.6 billion won, down 1.8% from 231.8 billion won the previous year. NOAC has attracted attention as a drug that has a lower risk of bleeding side effects than warfarin, a conventional anticoagulant, and has a great thromboembolic effect. A total of four original products are on sale. Since the early